Inspire's New CPT Codes Reshape the Business of Sleep Apnea

MINNEAPOLIS, MN – October 01, 2026 – For over a decade, the medical technology sector has watched hypoglossal nerve stimulation transition from a speculative novelty to a clinical mainstay. Now, the administrative infrastructure is finally catching up to the surgical innovation. Inspire Medical Systems announced today that the American Medical Association (AMA) CPT Editorial Panel has approved a new set of Category I Current Procedural Terminology (CPT) codes specifically covering single-lead hypoglossal nerve stimulation systems. Scheduled to take effect on January 1, 2028, this regulatory milestone fundamentally alters the commercial landscape for obstructive sleep apnea (OSA) treatments.

While a coding update might seem like bureaucratic minutiae, in the realm of medical technology, it is the lifeblood of commercial viability. For hospital administrators, surgical practice managers, and investors, the establishment of these dedicated Category I codes represents the removal of a massive operational bottleneck. It signals a transition from the cumbersome, often unpredictable realm of legacy billing into a streamlined, standardized era of reimbursement.

The Regulatory Milestone: Erasing Administrative Friction

To understand the significance of the AMA’s decision, one must look at the friction inherent in the current clinical workflow. Historically, surgeons implanting Inspire’s earlier devices—such as the Inspire IV, which utilized a three-component system including a distinct respiratory sensing lead—relied on existing CPT codes like 64582. However, medical hardware evolves rapidly. Inspire’s next-generation Inspire V system consolidated the architecture into a simplified two-component design: an implantable pulse generator (IPG) and a single stimulation lead that eliminates the need for a separate distal respiratory sensor.

This hardware elegance created an administrative headache. Billing for a simplified, single-lead system using codes designed for multi-component arrays often forces hospitals to navigate a maze of unlisted codes or mismatched descriptors, leading to claim denials, delayed payments, and extensive back-and-forth with insurers.

"This new CPT code language addresses the implantation of a single lead and an implantable pulse generator (IPG) including our recently launched Inspire V system," said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. "We appreciate the AMA creating dedicated codes that will create a clearer, more consistent path for coding and reimbursement, which we expect will reduce administrative burden for hospitals and physicians and support continued growth in patient access to Inspire therapy."

The application for these new codes did not occur in a vacuum. It was backed by significant clinical consensus, receiving crucial support from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), the American Academy of Sleep Medicine (AASM), and the International Surgical Sleep Society (ISSS). When major medical societies align to push for a permanent coding solution, it underscores a broad clinical demand to make a procedure a routine standard of care.

Competitive Moats and Commercial Realities

From a market intelligence perspective, the specificity of the AMA's new codes—expressly designating "single-lead" systems—creates a fascinating competitive dynamic. Inspire Medical Systems, having already treated more than 140,000 patients, commands a formidable first-mover advantage. The new codes essentially build a regulatory moat around the specific architecture of the Inspire V device.

Consider the broader competitive field. In August 2025, the FDA approved Nyxoah’s Genio system, a leadless device that utilizes bilateral stimulation and a non-implanted battery solution. Earlier this year, Medicare introduced new HCPCS codes to address various newer neurostimulators, including leadless variants. However, by securing Category I CPT codes specifically tailored to single-lead IPG systems, Inspire ensures that its exact technological approach is hardwired into the AMA’s permanent coding framework.

For hospital purchasing committees, predictability is paramount. When evaluating whether to scale up surgical sleep programs, administrators look for technologies with the least reimbursement friction. By locking in a dedicated Category I pathway, Inspire reduces the financial risk for healthcare facilities, effectively incentivizing them to standardize their OSA surgical offerings around the Inspire V architecture rather than gambling on unlisted codes for competing form factors.

The Path to 2028: Valuation and Rate-Setting

While the approval is finalized, the financial mechanics will be calibrated over the next fifteen months. The Centers for Medicare & Medicaid Services (CMS) will now initiate its standard process to determine the exact payment values for these new codes under the Medicare Physician Fee Schedule.

This involves the AMA Relative Value Scale Update Committee (RUC). Specialty societies like the AAO-HNS will survey their surgical members to quantify the physician time, technical complexity, and practice expenses—including clinical staff, equipment, and liability insurance—required to perform the single-lead implantation. These rigorous surveys form the basis of the RUC’s recommendations to CMS.

Industry analysts and practice managers will be watching the calendar closely. CMS is expected to publish its proposed reimbursement valuations in July 2027, with the final valuations cemented in November 2027, just weeks before the codes go live in January 2028.

For medtech investors, this timeline is a critical catalyst. The clarity of the impending 2028 implementation allows hospitals to begin budgeting and expanding their surgical training pipelines today, confident that the reimbursement infrastructure will be in place by the time new surgeons are fully ramped up.

Beyond the CPAP: Mainstreaming Surgical Sleep Therapy

Ultimately, the business of sleep medicine is driven by patient outcomes, and the patient paradigm is shifting dramatically. For decades, the Continuous Positive Airway Pressure (CPAP) machine has been the gold standard for moderate to severe OSA. Yet, clinical data consistently shows abysmal long-term compliance rates, with a significant percentage of patients unable to tolerate the masks, the noise, or the forced air.

Inspire’s closed-loop neurostimulation technology bypasses the airway obstruction by working internally, syncing with the patient's natural breathing to stimulate the hypoglossal nerve and keep the airway open. The transition from a three-component system to the single-lead Inspire V drastically reduced surgical time and complexity, minimizing the physical toll on the patient.

By securing Category I CPT codes, the AMA is effectively signaling that surgical neurostimulation is no longer an "alternative" therapy for a niche subset of patients; it is a mainstream, foundational pillar of sleep medicine. As the administrative barriers evaporate, general practitioners and sleep specialists will face fewer hurdles when referring CPAP-intolerant patients for surgical consultation.

The 2028 coding update is more than a win for Inspire Medical Systems’ balance sheet. It is a structural maturation of the sleep apnea market, ensuring that as hardware becomes more elegant and minimally invasive, the healthcare system is actually equipped to pay for it. For the millions of patients still struggling with traditional CPAP therapy, the path to surgical relief is about to become significantly wider.